Dr Anne Moore with microneedle patches on her hand Image Tomás Tyner
Researchers at UCC have developed a microneedle-based patch that results in increased vaccine-induced protection against malaria infection using lower doses of vaccine in pre-clinical testing.
The lead researcher, Dr Anne Moore, heads to Silicon Valley next week to meet venture capitalists and leading technology companies with a view to commercialising the research.
The microneedle-based patch also overcomes one of the main problems with this type of vaccine which relates to overcoming pre-existing immunity to the vaccine. The scientists combined two vaccine technologies to determine if immunity could be further enhanced and the research suggests that using a microneedle patch would overcome the need to make and use multiple different vaccine types to induce protective immunity to some of the world’s biggest killers. This could have significant consequences on the costs and logistics of vaccination.
The work was carried out by researchers in the School of Pharmacy, Dept. of Pharmacology and the Tyndall National Institute, UCC, led by Dr Anne Moore in collaboration with colleagues at the Jenner Institute, University of Oxford and was published byNature Publication Group in Scientific Reports and funded by Enterprise Ireland and Science Foundation Ireland. Dr Moore’s visit to Silicon Valley is being hosted by the Irish Technology Leadership Group (ITLG) as part of an SFI initiative for researchers to help them develop their entrepreneurial skills in the Get Started Venture Technology programme.
The skin patch has arrays of tiny silicon ‘microneedles’ that painlessly create temporary pores in the very outermost barrier layer of the skin, permitting the vaccine to flow into the skin, which is rich in cells of the immune system. The experimental vaccine was based on a live adenovirus. This virus is similar to those that can cause a common cold, but is engineered to be safer and to deliver a protein from the malaria-causing parasite, to the immune system.
The Latest on: Malaria vaccine
via Google News
The Latest on: Malaria vaccine
- The Military Can’t Get Troops to Take the Covid Vaccine. Come Again?on March 1, 2021 at 3:09 pm
A bout one-third of military service members are refusing to take the coronavirus vaccine. In some units, refusal rates exceed half of members. At a time when the virus remains as dangerous as ever, ...
- RNA technology used for COVID could lead to malaria vaccineon March 1, 2021 at 6:46 am
The RNA technology that helped us get a COVID vaccine may help the world get a vaccine for malaria, too.Driving the news: Scientists have applied for a patent for an RNA-based vaccine that might ...
- Vaccines Market: Analysis, Regional Trend, Share, Global Insights, Industry Growth, Revenue Projections By 2026on February 28, 2021 at 4:49 pm
The global “vaccines market” size is expected to be USD 93.08 billion by 2026, exhibiting a CAGR of 10.7% during ...
- mRNA vaccine technology could be used to protect against other deadly diseases: expertson February 28, 2021 at 11:44 am
To date, Canada has approved two mRNA vaccines for use to protect against COVID-19 -- one from Pfizer-BioNTech, the other from Moderna.
- Breakthrough made in vaccine against malaria using same tech for COVID-19on February 28, 2021 at 7:42 am
Scientists are working to develop a new vaccine against malaria, a disease that kills hundreds of thousands each year globally, using the same RNA-based technology used in some vaccines for COVID-19, ...
- Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Treatment Type ; Route of Administration ; End User and Geographyon February 23, 2021 at 2:28 am
Reportlinker.com announces the release of the report "Malaria Treatment Market Forecast to 2027 - COVID-19 Impact and ...
- Malaria Vaccines Market Size, Share and Growth to record over US $134.9 Mn by 2026on February 22, 2021 at 4:38 am
Global malaria vaccines market size is forecast to reach USD 134.9 million by 2026, growing at a CAGR of 33.2% during the estimated period, according to the latest research available at Market Study ...
- Antibody mediated activation of natural killer cells in malaria exposed pregnant womenon February 18, 2021 at 1:46 pm
Immune effector responses against Plasmodium falciparum include antibody-mediated activation of innate immune cells, which can induce Fc effector functions, including antibody-dependent cellular ...
- Cone snail venom shows potential for treating severe malariaon February 18, 2021 at 7:29 am
Severe forms of malaria such as Plasmodium falciparum may be deadly even after treatment with current parasite-killing drugs. This is due to persistent cyto-adhesion of infected erythrocytes even ...
- Cone snail venom could potentially treat severe forms of malariaon February 18, 2021 at 6:12 am
Severe forms of malaria such as Plasmodium falciparum may be deadly even after treatment with current parasite-killing drugs.
via Bing News
